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L E T T E R  T O  T H E  E D I T O R
Pregabalin: A range of misuse‐related unanswered questions
Although	initially	marketed	as	having	a	low	abuse	potential,	further	
recent,	 large‐scale,	 papers1	 have	 once	 again	 convincingly	 empha‐
sized	the	pregabalin	potential	of	misuse.	However,	after	a	decade	of	
intensive	pregabalin‐focused	studies,	still	a	few	issues	remain	open.
Indeed,	the	first	to	explore	is	why	a	potential	for	misuse	for	pre‐
gabalin	is	there.	Is	it	related	to	a	direct/indirect	dopaminergic	activity	
similar	to	remaining	drugs	of	misuse?	Why	is	pregabalin	being	typically	
misused	in	combination	with	opiates/opioids?	Pregabalin	is	a	known	
inhibitor	of	α2δ‐subunit‐containing	voltage‐dependent	calcium	chan‐
nels.2	The	entry	of	calcium	 ions	 into	neurons	allows	 the	process	of	
vesicle	fusion	with	the	cell	membrane,	which	facilitates	proper	release	
of	neurotransmitters.	Ultimately,	the	potent	binding	of	pregabalin	at	
the	calcium	channel	will	 reduce	the	release	of	excitatory	molecules	
(eg,	 glutamate,	 noradrenaline,	 and	 substance	 P,	 but	 not	 dopamine),	
acting	 against	 aberrant	 neuronal	 stimulation.2	 Several	 addictive	
drugs	have	 in	common	that	 they	 increase	 the	extracellular	dopami‐
nergic	activity	in	the	mesolimbic	reward	system.3	In	rats,	conditioned	
place	preference	was,	however,	 induced	only	with	high	 intraperito‐
neal	(but	not	oral)	pregabalin	doses,	restricting	the	ability	to	develop	
a	substantial	addictive	power.4	Accordingly,	patients	reported	pleas‐
ant	stimulation	and	euphoria	when	using	supratherapeutic/mega	(eg	
1500‐12	000	mg)	pregabalin	dosages.5,6	Hence,	one	could	wonder	if	
there	may	be	a	different/unclear	range	of	neurotransmitter	involve‐
ment,	and	receptors’	activation	intensity,	in	high/very	high	pregabalin	
dosage	ingestion.	Overall,	similar	to	what	was	observed	with	a	range	
of	 further	medications	 (eg,	 venlafaxine,	 bupropion,	 quetiapine,	 and	
loperamide),6	it	has	been	suggested	that	gabapentinoids	may	induce	
a	“liking”	(euphoric	high)	subjective	feeling,	due	to	their	gamma‐am‐
inobutyric	 acid	 (GABA)‐mimetic	 action,	 but	 more	 limited	 levels	 of	
“wanting”/behavioral	dependence.7	Cairns	et	al1	have	identified	that	
pregabalin	was	typically	ingested	in	combination	with	opiates/opioids.	
Indeed,	opioids	may	well	be	prescribed	to	potentiate	gabapentinoid	
analgesic	 effects	 for	 treating	 specific	 medical	 conditions/intracta‐
ble	pain.5	However,	pregabalin	may	clinically	counteract	the	opioids’	
withdrawal	effects	while	presenting	as	well	with	potentiating	effects	
when	given	to	mice	with	existing	opioid	levels.8
Second,	it	has	been1	suggested	that	the	misuse	of	pregabalin	may	
typically	be	associated	with	a	history	of	polydrug	misuse.	However,	
what	is	the	potential	for	misuse	among	those	with	different	drug	use	
experiences	and	who	may	not	increase	dosages	overtime?	According	
to	Bonnet	and	Scherbaum7	with	 respect	 to	 remaining	 recreational	
drugs	of	misuse,	there	is	less	evidence	for	gabapentinoids	being	mis‐
used	 in	a	 long‐term	manner.	However,	 there	are	no	 formal	data	 in	
the	 literature	about	clients	who	have	voluntarily	sought	treatment	
for	their	pregabalin	addiction	or	pregabalin	relapses	after	detoxifi‐
cation.7	Although	observations	of	behavioral	dependence	were	de‐
scribed	in	patients	who	had	no	prior	substance	abuse	history,	these	
cases	appeared	to	be	quite	rare.7	Kapil	et	al9 used an online survey 
to	assess	the	self‐reported	lifetime	prevalence	of	misuse	of	GABA‐
analogues	 in	 the	 younger	 and	mid‐life	UK	 general	 population	 and	
found	that	gabapentin	and	pregabalin	were,	respectively,	being	mis‐
used	by	1.1%	and	0.5%	of	 the	survey's	 respondents.	Further	valid	
prevalence	data	of	gabapentinoid	abuse	from	large‐scale	structured	
interviews	have	recently	been	made.	Snellgrove	et	al10	carried	out	
a	cross‐sectional	 study	with	 some	253	addicts	on	a	detoxification	
ward	in	southern	Germany.	They	found	that	some	56%	had	used	pre‐
gabalin	at	least	once	and	that	DSM‐IV	dependence	criteria	were	met	
by	11%	of	pregabalin	users.	Further	systematic	prevalence	data	from	
a	cohort	of	400	randomly	selected	elderly	hospitalized	population	
were	provided	by	Cossmann	et	al11	A	fifth	of	the	cohort	was	found	
to	be	mildly	dependent	on	nonopioid	analgesics,	but	one	case	with	a	
previous	dependence	on	gabapentinoids	was	identified
Third,	 in	many	studies1,5	 it	was	unclear	 if	pregabalin	was	most	
typically	prescribed	 to	 those	affected	by	anxiety	 conditions	 to	ei‐
ther	 “boost”	 and/or	 to	 replace	 existing	 benzodiazepine	 prescrip‐
tions.	Is	the	pregabalin	state	of	mind	different	from	that	associated	
with	benzodiazepines’	intake?	Even	though	pregabalin	is	structurally	
related	to	GABA,	and	although	there	are	not	any	known	direct	ac‐
tions	on	GABA	or	its	receptors,	therapeutic	doses	of	pregabalin	are	
dose‐dependently	 associated	 with	 increase	 in	 extracellular	 GABA	
levels.7	Most	 likely,	 this	 drives	 the	 relaxation	 and	 euphoria	which	
are	reported	at	 the	commencement	of	prescribed	pregabalin	use.7 
However,	 different	 from	 clonazepam,	 high‐dosage	 pregabalin	 has	
been	anecdotally	described	as	an	“ideal	psychotropic	drug”	for	rec‐
reational	purposes	to	achieve	specific	mindsets,	including	relaxation	
and	disinhibition,	for	example,	alcohol/GHB/benzodiazepine‐like	ef‐
fects	mixed	with	euphoria;	to	achieve	entactogenic	feelings/dissoci‐
ation;	and	to	cope	with	opiate/opioid	withdrawal.10,12
Consistent	with	 these	 concerns,	 the	 rate	 of	 pregabalin‐related	
ambulance	attendances	has	recently	increased13	and	growing	num‐
bers	of	deaths	have	been	associated	with	pregabalin	misuse.	These	
misusing	levels	mostly	occur	together	with	other	sedatives,	such	as	
benzodiazepines,	alcohol,	and	opioids.13,14	 In	all	 these	polydrug	 in‐
toxication	 cases,	pregabalin,	while	 contributing	 in	 terms	of	overall	
central	nervous	system	depression,1,6	may	well	have	worsened	the	
observed	clinical	outcomes.	However,	one	could	still	argue	that	at	
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least	 in	 some	cases,	 pregabalin	may	be	 identified	 as	 just	 an	easily	
accessible	molecule	with	a	“liking”	feature,	and	this	issue	may	need	
more	debate	and	research….’.
Both	pregabalin	and	gabapentin	have	been	reclassified	as	class	C	
controlled	substances	in	the	UK.	Nonetheless,	in	the	US,	pregabalin	
is	designated	as	a	Schedule	V	controlled	substance,	while	gabapentin	
is	a	controlled	substance	only	in	some	states	(Tennessee,	Kentucky).	
Moreover,	in	Australia,	pregabalin	and	gabapentin	are	still	classified	
as	Prescription	Only	(Schedule	4)	medications,	meaning	that,	similar	
todrugs	like	statins	and	antibiotics,	they	are	not	associated	with	any	
special	controls	on	supply	or	possession.13	It	is	here	suggested	that,	
whenever	psychotropics	are	to	be	made	available	on	prescription,	a	
range	of	abuse	liability‐focused	and	pre‐marketing	laboratory	test‐
ing	may	need	to	be	carried	out.	These	phase	3	studies	should	also	
assess	 how	 the	 new	drug	may	 interact	with	 alcohol	 and/or	 other	
drugs.	Also,	post‐marketing	surveillance	studies	should	be	encour‐
aged	to	more	accurately	assess	 the	true	misusing	potential	of	any	
psychotropic	molecule.	Physicians	should	be	vigilant	when	prescrib‐
ing	drugs	with	a	misuse/diversion	potential	and	carefully	evaluate	
the	possibility	 that	some	clients	 (including	people	with	a	personal	
history	of	drug	misuse	or	abuse)	may	be	more	vulnerable.
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